Sandhoff Disease Therapeutics Market Snapshot (2023 to 2033)

The global Sandhoff Disease Therapeutics Market is expected to garner a market value of US$10 Million in 2023 and is expected to accumulate a market value of US$ 17.91 Million by registering a CAGR of 6% in the forecast period 2023 to 2033. The market for Sandhoff Disease Therapeutics registered a CAGR of 4% in the historical period 2018 to 2022.

The Sandhoff Disease Therapeutics market is a segment of the healthcare industry that deals with the effective management of the condition. The Sandhoff Disease Therapeutics market offers a range of products and services for its effective management and treatment such as physical therapy, seizure medications, and other supportive care measures such as Genetic counseling and prenatal testing.

Report Attribute Details
Expected Market Value (2023) US$10 Million
Anticipated Forecast Value (2033) US$ 17.91 Million
Projected Growth Rate (2023 to 2033) 6% CAGR

Don't pay for what you don't need

Customize your report by selecting specific countries or regions and save 30%!

2018 to 2022 Sandhoff Disease Therapeutics Market Demand Analysis vs. Forecast 2023 to 2033

According to market research and competitive intelligence provider, Future Market Insights- the market for Sandhoff Disease Therapeutics reflected a value of 4% during the historical period, 2018 to 2022.

The market for Sandhoff Disease Therapeutics is gaining prominence as it is considered a rare genetic disorder that affects the nervous system. Furthermore, due to the rarity of the disease, there is ongoing research into developing new treatments for sandhoff disease therapeutics, expected to drive demand for these treatments.

The development of new treatments is a high priority for the medical community due to the devastating effects of the disease and the limited treatment options available. As more effective treatments become available, the market for Sandhoff Disease Therapeutics is likely to grow. In the years to come, increasing focus by government organizations and private agencies like WHO and pharmaceutical companies to create awareness of Sandhoff Disease Therapeutics is fuelling the market growth. Thus, the market for Sandhoff Disease Therapeutics is expected to register a CAGR of 6% in the forecast period 2023 to 2033.

Which are Some Prominent Drivers of the Sandhoff Disease Therapeutics Market?

Growing advancements in diagnostic and treatment options to push the market growth

The global market for Sandhoff Disease Therapeutics is primarily driven by an increased awareness of the disease among healthcare professionals, advances in genetic testing and diagnosis, and ongoing research and development efforts towards the development of new and effective treatment options and technologies. According to the latest studies, Sandhoff disease is a rare disorder that is estimated to affect 1 in 1,000,000 individuals.

The growth of the Sandhoff Disease Therapeutics market is owed to the increasing prevalence of the condition owing to the increasing use of gene therapy, enzyme replacement therapy, and small molecule drugs. These treatments have shown promising results in preclinical and early-stage clinical trials, and if they are successful in later-stage trials and gain regulatory approval, they could significantly impact the Sandhoff disease therapeutics market. As a result, the players in the market are working on the development of new diagnostic tools and techniques that are likely to improve the accuracy of Sandhoff Disease Therapeutics.

For instance, in February 2021, Sio Gene Therapies made the announcement of the first patient being dosed with AXO-AAV-GM2, which is a significant milestone for the company as well as for the field of gene therapy. The goal of the Phase 1/2 trial is to evaluate the safety and efficacy of AXO-AAV-GM2, which has the potential to restore lysosomal enzyme activity and potentially change the course of the disease.

Sabyasachi Ghosh
Sabyasachi Ghosh

Principal Consultant

Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

What are the Challenges Faced by the Sandhoff Disease Therapeutics Market?

Expensive Cost of Treatment to restrict Market Growth

The market is projected to get significantly affected by the challenging factors such as limited availability and high cost of advanced Sandhoff Disease Therapeutics options. Expensive treatments and related costs such as hospitalization, intensive care, or specialized diagnostic tests, is expected to hinder the market growth. Furthermore, poor healthcare infrastructure, especially in developing countries, can limit access to Sandhoff Disease Therapeutics and the availability of diagnostic and therapeutic options.

Region-Wise Insights

How is the Sandhoff Disease Therapeutics Market Turning Out in the South & East Asian Region?

Improvement in healthcare spending propelling growth of market in Asia Pacific

The South & East Asia region is expected to exhibit the significant growth rate of all regions over the forecast period, with a share of 20% during the forecast period. The growth is owed to increased awareness and prevalence of Sandhoff Disease, significant increases in healthcare spending, and the growing investments in research and development of innovative therapies in the region. South Asia is an emerging market due to the increase in point of care approach to health & care. Increasing number of hospitals in India and China makes a promising market for the market worldwide.

What are the Factors Boosting the Market for Sandhoff Disease Therapeutics in North America?

Increasing Focus on R&D Shaping Landscape for Sandhoff Disease Therapeutics in North America

North America is anticipated to acquire a market share of about 40% in the forecast period. This growth is attributable to the rising prevalence of the condition in the region along with the high healthcare expenditure and a large geriatric population. The United States of America holds the highest share in the North American market, followed by Canada. Presence of a large number of pharmaceutical companies, which are investing heavily in the development of new, targeted treatments for the condition, and high level of healthcare expenditure leading to a large patient population are some of the factors responsible for the growth of the market in the region.

Get the data you need at a Fraction of the cost

Personalize your report by choosing insights you need
and save 40%!

Category-Wise Insights

By therapy, Which Segment is Likely to Account for a Significant Share?

Rising prevalence of gene therapy to push market growth

According to the studies, Gene therapy is being researched as a potential treatment for Sandhoff disease. The therapy works by introducing a functional copy of the missing enzyme into the patient's cells, thereby restoring the ability to break down GM2 ganglioside. This can potentially slow or stop the progression of the disease, and improve the patient's quality of life.

Gene therapy is still in the early stages of development and clinical trials are underway to determine its safety and efficacy. However, it has the potential to be a one-time treatment that could change the lives of patients suffering from GM2 gangliosidosis and provide a new hope for a cure.

By End User, Which Segment is Likely to Account for a Significant Share?

Hospitals to take the lead and drive market growth

According to the FMI analysis, Hospitals account for the largest market share. The requirement for several hospital stays and visits during the Sandhoff Disease Therapeutics treatment facilitates the growth of this segment. Majority of the serious diseases involving the nervous system are treated in hospitals, and with the availability of trained medical personnel, it is simpler to control an individual's health more correctly.

Market Competition

Key players in the market include pharmaceutical companies such as Bioasis Technologies Inc, Nuo Therapeutics Inc, Sio Gene Therapies, Inc., INTRABIO IRELAND LIMITED, Sanofi, ROIVANT SCIENCES LTD, Azafaros, Polaryx Therapeutics, Abbott Medtronic, and Merck & Co., Inc. along with healthcare providers and technology companies among other global players.

  • In November 2020, Axovant Gene Therapies Ltd., a company developing gene therapies, announced that the FDA has cleared its Investigational New Drug Application to start a registrational study of AXO-AAV-GM2 gene therapy for Tay-Sachs and Sandhoff diseases. AXO-AAV-GM2 is the first gene therapy to receive IND clearance for these diseases. The FDA letter confirms that all issues related to the clinical hold have been resolved. This marks a significant moment for the GM2 gangliosidosis community and is the second IND clearance for Axovant's gene therapy pipeline in the last year, with the first being AXO-AAV-GM1 for GM1 gangliosidosis.

Report Scope

Report Attribute Details
Market Value in 2023 US$10 Million
Market Value in 2033 US$ 17.91 Million
Growth Rate CAGR of 6% from 2023 to 2033
Base Year for Estimation 2022
Historical Data 2018 to 2022
Forecast Period 2023 to 2033
Quantitative Units Revenue in USD Million and CAGR from 2023 to 2033
Report Coverage Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends and Pricing Analysis
Segments Covered
  • Therapy
  • Type
  • End-Users
  • Region
Regions Covered
  • North America
  • Latin America
  • Europe
  • South Asia
  • East Asia
  • Oceania
  • Middle East & Africa
Key Countries Profiled
  • USA
  • Canada
  • Brazil
  • Mexico
  • Rest of Latin America
  • Germany
  • United Kingdom
  • France
  • Spain
  • Italy
  • Rest of Europe
  • Malaysia
  • Singapore
  • China
  • India
  • Thailand
  • Rest of South Asia
  • Gulf Cooperation Council
  • Japan
  • South Korea
  • Australia
  • New Zealand
  • GCC countries
  • South Africa
  • Israel
  • Rest of MEA
Key Companies Profiled NeoImmuneTech, Neurimmune, GlaxoSmithKline Plc, Sanofi S.A., Gilead Sciences, Inc., Allergan Plc., Novartis AG, AbbVie Inc., and Bristol-Myers Squibb Company
Customization Available Upon Request

Key Segments Profiled in the Sandhoff Disease Therapeutics Industry Survey

Therapy:

  • Gene Therapy
  • Enzyme Replacement Therapy
  • Stem Cell Therapy

Type:

  • Acute infantile Sandhoff disease
  • Subacute juvenile Sandhoff disease
  • Late-onset Sandhoff disease

End-Users:

  • Hospitals
  • Homecare
  • Specialty Clinics

Region:

  • North America
  • Latin America
  • Europe
  • East Asia
  • South Asia
  • Oceania
  • Middle East & Africa

Frequently Asked Questions

What is the market value in 2023?

The market in 2023 is valued at US$ US$10 million.

What will the market value be in 2033?

By 2033, the market will reach US$ 17.91 million.

What is the growth rate of the market through 2033?

The market will expand at a 6% CAGR through 2033.

How did the market expand historically?

From 2018 to 2022, the market rose at a 4% CAGR.

What is the North America market outlook in 2023?

In 2023, North America accounts for 40% revenue.

Table of Content

1. Executive Summary | Sandhoff Disease Therapeutics Market

    1.1. Global Market Outlook

    1.2. Demand-side Trends

    1.3. Supply-side Trends

    1.4. Technology Roadmap Analysis

    1.5. Analysis and Recommendations

2. Market Overview

    2.1. Market Coverage / Taxonomy

    2.2. Market Definition / Scope / Limitations

3. Market Background

    3.1. Market Dynamics

        3.1.1. Drivers

        3.1.2. Restraints

        3.1.3. Opportunity

        3.1.4. Trends

    3.2. Scenario Forecast

        3.2.1. Demand in Optimistic Scenario

        3.2.2. Demand in Likely Scenario

        3.2.3. Demand in Conservative Scenario

    3.3. Opportunity Map Analysis

    3.4. Investment Feasibility Matrix

    3.5. PESTLE and Porter’s Analysis

    3.6. Regulatory Landscape

        3.6.1. By Key Regions

        3.6.2. By Key Countries

    3.7. Regional Parent Market Outlook

4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033

    4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022

    4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033

        4.2.1. Y-o-Y Growth Trend Analysis

        4.2.2. Absolute $ Opportunity Analysis

5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Type

    5.1. Introduction / Key Findings

    5.2. Historical Market Size Value (US$ Million) Analysis By Type, 2018 to 2022

    5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Type, 2023 to 2033

        5.3.1. Acute infantile Sandhoff disease

        5.3.2. Subacute juvenile Sandhoff disease

        5.3.3. Late-onset Sandhoff disease

    5.4. Y-o-Y Growth Trend Analysis By Type, 2018 to 2022

    5.5. Absolute $ Opportunity Analysis By Type, 2023 to 2033

6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Therapy

    6.1. Introduction / Key Findings

    6.2. Historical Market Size Value (US$ Million) Analysis By Therapy, 2018 to 2022

    6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Therapy, 2023 to 2033

        6.3.1. Gene Therapy

        6.3.2. Enzyme Replacement Therapy

        6.3.3. Stem Cell Therapy

    6.4. Y-o-Y Growth Trend Analysis By Therapy, 2018 to 2022

    6.5. Absolute $ Opportunity Analysis By Therapy, 2023 to 2033

7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By End-Users

    7.1. Introduction / Key Findings

    7.2. Historical Market Size Value (US$ Million) Analysis By End-Users , 2018 to 2022

    7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By End-Users , 2023 to 2033

        7.3.1. Hospitals

        7.3.2. Homecare

        7.3.3. Specialty Clinics

    7.4. Y-o-Y Growth Trend Analysis By End-Users , 2018 to 2022

    7.5. Absolute $ Opportunity Analysis By End-Users , 2023 to 2033

8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region

    8.1. Introduction

    8.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022

    8.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033

        8.3.1. North America

        8.3.2. Latin America

        8.3.3. Europe

        8.3.4. South Asia

        8.3.5. East Asia

        8.3.6. Oceania

        8.3.7. MEA

    8.4. Market Attractiveness Analysis By Region

9. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        9.2.1. By Country

            9.2.1.1. The USA

            9.2.1.2. Canada

        9.2.2. By Type

        9.2.3. By Therapy

        9.2.4. By End-Users

    9.3. Market Attractiveness Analysis

        9.3.1. By Country

        9.3.2. By Type

        9.3.3. By Therapy

        9.3.4. By End-Users

    9.4. Key Takeaways

10. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        10.2.1. By Country

            10.2.1.1. Brazil

            10.2.1.2. Mexico

            10.2.1.3. Rest of Latin America

        10.2.2. By Type

        10.2.3. By Therapy

        10.2.4. By End-Users

    10.3. Market Attractiveness Analysis

        10.3.1. By Country

        10.3.2. By Type

        10.3.3. By Therapy

        10.3.4. By End-Users

    10.4. Key Takeaways

11. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        11.2.1. By Country

            11.2.1.1. Germany

            11.2.1.2. United Kingdom

            11.2.1.3. France

            11.2.1.4. Spain

            11.2.1.5. Italy

            11.2.1.6. Rest of Europe

        11.2.2. By Type

        11.2.3. By Therapy

        11.2.4. By End-Users

    11.3. Market Attractiveness Analysis

        11.3.1. By Country

        11.3.2. By Type

        11.3.3. By Therapy

        11.3.4. By End-Users

    11.4. Key Takeaways

12. South Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        12.2.1. By Country

            12.2.1.1. India

            12.2.1.2. Malaysia

            12.2.1.3. Singapore

            12.2.1.4. Thailand

            12.2.1.5. Rest of South Asia

        12.2.2. By Type

        12.2.3. By Therapy

        12.2.4. By End-Users

    12.3. Market Attractiveness Analysis

        12.3.1. By Country

        12.3.2. By Type

        12.3.3. By Therapy

        12.3.4. By End-Users

    12.4. Key Takeaways

13. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        13.2.1. By Country

            13.2.1.1. China

            13.2.1.2. Japan

            13.2.1.3. South Korea

        13.2.2. By Type

        13.2.3. By Therapy

        13.2.4. By End-Users

    13.3. Market Attractiveness Analysis

        13.3.1. By Country

        13.3.2. By Type

        13.3.3. By Therapy

        13.3.4. By End-Users

    13.4. Key Takeaways

14. Oceania Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        14.2.1. By Country

            14.2.1.1. Australia

            14.2.1.2. New Zealand

        14.2.2. By Type

        14.2.3. By Therapy

        14.2.4. By End-Users

    14.3. Market Attractiveness Analysis

        14.3.1. By Country

        14.3.2. By Type

        14.3.3. By Therapy

        14.3.4. By End-Users

    14.4. Key Takeaways

15. MEA Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    15.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    15.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        15.2.1. By Country

            15.2.1.1. GCC Countries

            15.2.1.2. South Africa

            15.2.1.3. Israel

            15.2.1.4. Rest of MEA

        15.2.2. By Type

        15.2.3. By Therapy

        15.2.4. By End-Users

    15.3. Market Attractiveness Analysis

        15.3.1. By Country

        15.3.2. By Type

        15.3.3. By Therapy

        15.3.4. By End-Users

    15.4. Key Takeaways

16. Key Countries Market Analysis

    16.1. USA

        16.1.1. Pricing Analysis

        16.1.2. Market Share Analysis, 2022

            16.1.2.1. By Type

            16.1.2.2. By Therapy

            16.1.2.3. By End-Users

    16.2. Canada

        16.2.1. Pricing Analysis

        16.2.2. Market Share Analysis, 2022

            16.2.2.1. By Type

            16.2.2.2. By Therapy

            16.2.2.3. By End-Users

    16.3. Brazil

        16.3.1. Pricing Analysis

        16.3.2. Market Share Analysis, 2022

            16.3.2.1. By Type

            16.3.2.2. By Therapy

            16.3.2.3. By End-Users

    16.4. Mexico

        16.4.1. Pricing Analysis

        16.4.2. Market Share Analysis, 2022

            16.4.2.1. By Type

            16.4.2.2. By Therapy

            16.4.2.3. By End-Users

    16.5. Germany

        16.5.1. Pricing Analysis

        16.5.2. Market Share Analysis, 2022

            16.5.2.1. By Type

            16.5.2.2. By Therapy

            16.5.2.3. By End-Users

    16.6. United Kingdom

        16.6.1. Pricing Analysis

        16.6.2. Market Share Analysis, 2022

            16.6.2.1. By Type

            16.6.2.2. By Therapy

            16.6.2.3. By End-Users

    16.7. France

        16.7.1. Pricing Analysis

        16.7.2. Market Share Analysis, 2022

            16.7.2.1. By Type

            16.7.2.2. By Therapy

            16.7.2.3. By End-Users

    16.8. Spain

        16.8.1. Pricing Analysis

        16.8.2. Market Share Analysis, 2022

            16.8.2.1. By Type

            16.8.2.2. By Therapy

            16.8.2.3. By End-Users

    16.9. Italy

        16.9.1. Pricing Analysis

        16.9.2. Market Share Analysis, 2022

            16.9.2.1. By Type

            16.9.2.2. By Therapy

            16.9.2.3. By End-Users

    16.10. India

        16.10.1. Pricing Analysis

        16.10.2. Market Share Analysis, 2022

            16.10.2.1. By Type

            16.10.2.2. By Therapy

            16.10.2.3. By End-Users

    16.11. Malaysia

        16.11.1. Pricing Analysis

        16.11.2. Market Share Analysis, 2022

            16.11.2.1. By Type

            16.11.2.2. By Therapy

            16.11.2.3. By End-Users

    16.12. Singapore

        16.12.1. Pricing Analysis

        16.12.2. Market Share Analysis, 2022

            16.12.2.1. By Type

            16.12.2.2. By Therapy

            16.12.2.3. By End-Users

    16.13. Thailand

        16.13.1. Pricing Analysis

        16.13.2. Market Share Analysis, 2022

            16.13.2.1. By Type

            16.13.2.2. By Therapy

            16.13.2.3. By End-Users

    16.14. China

        16.14.1. Pricing Analysis

        16.14.2. Market Share Analysis, 2022

            16.14.2.1. By Type

            16.14.2.2. By Therapy

            16.14.2.3. By End-Users

    16.15. Japan

        16.15.1. Pricing Analysis

        16.15.2. Market Share Analysis, 2022

            16.15.2.1. By Type

            16.15.2.2. By Therapy

            16.15.2.3. By End-Users

    16.16. South Korea

        16.16.1. Pricing Analysis

        16.16.2. Market Share Analysis, 2022

            16.16.2.1. By Type

            16.16.2.2. By Therapy

            16.16.2.3. By End-Users

    16.17. Australia

        16.17.1. Pricing Analysis

        16.17.2. Market Share Analysis, 2022

            16.17.2.1. By Type

            16.17.2.2. By Therapy

            16.17.2.3. By End-Users

    16.18. New Zealand

        16.18.1. Pricing Analysis

        16.18.2. Market Share Analysis, 2022

            16.18.2.1. By Type

            16.18.2.2. By Therapy

            16.18.2.3. By End-Users

    16.19. GCC Countries

        16.19.1. Pricing Analysis

        16.19.2. Market Share Analysis, 2022

            16.19.2.1. By Type

            16.19.2.2. By Therapy

            16.19.2.3. By End-Users

    16.20. South Africa

        16.20.1. Pricing Analysis

        16.20.2. Market Share Analysis, 2022

            16.20.2.1. By Type

            16.20.2.2. By Therapy

            16.20.2.3. By End-Users

    16.21. Israel

        16.21.1. Pricing Analysis

        16.21.2. Market Share Analysis, 2022

            16.21.2.1. By Type

            16.21.2.2. By Therapy

            16.21.2.3. By End-Users

17. Market Structure Analysis

    17.1. Competition Dashboard

    17.2. Competition Benchmarking

    17.3. Market Share Analysis of Top Players

        17.3.1. By Regional

        17.3.2. By Type

        17.3.3. By Therapy

        17.3.4. By End-Users

18. Competition Analysis

    18.1. Competition Deep Dive

        18.1.1. Bioasis Technologies Inc

            18.1.1.1. Overview

            18.1.1.2. Product Portfolio

            18.1.1.3. Profitability by Market Segments

            18.1.1.4. Sales Footprint

            18.1.1.5. Strategy Overview

                18.1.1.5.1. Marketing Strategy

        18.1.2. Nuo Therapeutics Inc

            18.1.2.1. Overview

            18.1.2.2. Product Portfolio

            18.1.2.3. Profitability by Market Segments

            18.1.2.4. Sales Footprint

            18.1.2.5. Strategy Overview

                18.1.2.5.1. Marketing Strategy

        18.1.3. Sio Gene Therapies, Inc.

            18.1.3.1. Overview

            18.1.3.2. Product Portfolio

            18.1.3.3. Profitability by Market Segments

            18.1.3.4. Sales Footprint

            18.1.3.5. Strategy Overview

                18.1.3.5.1. Marketing Strategy

        18.1.4. INTRABIO IRELAND LIMITED

            18.1.4.1. Overview

            18.1.4.2. Product Portfolio

            18.1.4.3. Profitability by Market Segments

            18.1.4.4. Sales Footprint

            18.1.4.5. Strategy Overview

                18.1.4.5.1. Marketing Strategy

        18.1.5. Sanofi

            18.1.5.1. Overview

            18.1.5.2. Product Portfolio

            18.1.5.3. Profitability by Market Segments

            18.1.5.4. Sales Footprint

            18.1.5.5. Strategy Overview

                18.1.5.5.1. Marketing Strategy

        18.1.6. ROIVANT SCIENCES LTD.

            18.1.6.1. Overview

            18.1.6.2. Product Portfolio

            18.1.6.3. Profitability by Market Segments

            18.1.6.4. Sales Footprint

            18.1.6.5. Strategy Overview

                18.1.6.5.1. Marketing Strategy

        18.1.7. Azafaros

            18.1.7.1. Overview

            18.1.7.2. Product Portfolio

            18.1.7.3. Profitability by Market Segments

            18.1.7.4. Sales Footprint

            18.1.7.5. Strategy Overview

                18.1.7.5.1. Marketing Strategy

        18.1.8. Polaryx Therapeutics

            18.1.8.1. Overview

            18.1.8.2. Product Portfolio

            18.1.8.3. Profitability by Market Segments

            18.1.8.4. Sales Footprint

            18.1.8.5. Strategy Overview

                18.1.8.5.1. Marketing Strategy

        18.1.9. Abbott Medtronic

            18.1.9.1. Overview

            18.1.9.2. Product Portfolio

            18.1.9.3. Profitability by Market Segments

            18.1.9.4. Sales Footprint

            18.1.9.5. Strategy Overview

                18.1.9.5.1. Marketing Strategy

        18.1.10. Merck & Co., Inc.

            18.1.10.1. Overview

            18.1.10.2. Product Portfolio

            18.1.10.3. Profitability by Market Segments

            18.1.10.4. Sales Footprint

            18.1.10.5. Strategy Overview

                18.1.10.5.1. Marketing Strategy

19. Assumptions & Acronyms Used

20. Research Methodology

Recommendations

Healthcare

Neurointerventional Device Market

August 2020

REP-GB-871

October 2023

223 pages

Healthcare

Spinal Cord Stimulators Market

July 2017

REP-GB-2030

September 2023

324 pages

Healthcare

Brain Imaging And Neuroimaging Market

September 2016

REP-GB-1841

July 2023

319 pages

Healthcare

Rare Neurological Disease Treatment Market

March 2018

REP-GB-6445

February 2023

170 pages

Explore Healthcare Insights

View Reports
Future Market Insights

Sandhoff Disease Therapeutics Market